Call Now
Closest Clinic to Pleasant Prairie, WI
Semaglutide Medical Weight Loss Near Pleasant Prairie, WI
Though health and wellness trends are on the rise in America, millions of men and women in our country find it hard to lose weight and keep it off. According to the CDC, from 2017-2020, almost 42% of adults over 20 were obese. 9.2% were severely obese. That breaks down to 100 million adults being obese and more than 22 million being severely obese. One glance at those stats, and it's clear that we have an obesity problem in the U.S.
Though many adults try dieting and going to the gym, they can't maintain the routine and never accomplish the weight loss goals they set for themselves. They notice extra fat around their stomach, arms, stomach, and neck. While those fat deposits are unsightly, they're also a sign that serious health issues could be around the corner, like stroke or heart disease. That should be concerning for all who are reading this, but especially for commercial drivers, who often don't have access to reliable healthcare.
The good news? Interstate Health now offers Semaglutide and Tirzepatide medical weight loss in Pleasant Prairie, WI for the men and women traversing our local and national highways. Unlike fad diets and risky weight loss pills, these two new revolutionary weight loss aides help you lose weight and keep it off so you can stay healthy on the road.
Meeting the Weight Loss Needs of Drivers and Local Communities
For too long, the professional drivers on which the transportation industry depends have been unable to reliably access healthcare and fitness centers to optimize their health. Drivers have had little choice but to delay or forgo their weight loss goals because traditional clinics and hospitals can't cater to them. Taking time off the road to lose weight and get healthy feels risky. Interstate Health is on a mission to change that feeling with physician-led weight loss plans supplemented with Tirzepatide or Semaglutide treatments.
Understanding the Interstate Health Weight Loss Difference
At Interstate Health, we offer straightforward weight loss plans that focus on helping you lose weight in a safe and healthy way while you're on the road. Our program provides you with the weight loss treatments, accountability, and guidance you need to shed pounds. Our top priority is to help you reach your desired weight safely and effectively, even when you're traveling across the country or live in a remote area.
Of course, it's up to you to incorporate lifestyle changes like diet and exercise, but we'll be in touch throughout your weight loss program to help you stay on course. When you stop in at one of our weight loss clinics along your route, we'll monitor your progress and overall health to ensure you're on track. The purpose of Tirzepatide and Semaglutide medical weight loss in Pleasant Prairie, WI is to provide you with comprehensive weight loss treatments that help you achieve natural, long-lasting results. That's the Interstate Health difference.
Patients who use our clinic for medical weight loss report exciting results, such as:
- More Energy
- Less Fatigue
- Better Sleep
- Improved Mood
- Lower Cholesterol
- Lower Blood Pressure
- Improved Blood Sugar Levels
- Much More
When you trust Interstate Health to help you lose weight, you can rest easy knowing our doctors and weight loss experts are there for you, whether you're on a multi-state delivery or in an area with poor healthcare access.
Does Tirzepatide Medical Weight Loss in Pleasant Prairie, WI Really Work?
Weight loss treatments like Tirzepatide are relatively new to the market, so it's normal to wonder if they really work to help you lose weight effectively. The short answer? Yes, they absolutely do.
Tirzepatide, a naturally occurring compound in your body, plays a crucial role in performing various essential bodily functions. It's designed to mimic the actions of hormones known as 'glucagon-like peptide-1' (GLP-1) and 'glucose-dependent insulinotropic polypeptide' (GIP). This unique ability to mimic two different types of hormones sets Tirzepatide apart and makes it more effective in promoting weight loss.
GLP-1 Hormones Explained
To understand why Semaglutide and Tirzepatide are so effective, you've got to first understand GLP-1 hormones.
Your brain manages and controls your body through a variety of control mechanisms, one of which involves your body's hormone system. These hormones play a role in regulating bodily functions such as digestion and metabolism. GLP-1, also known as glucagon-like peptide-1, belongs to a class of hormones that assist in regulating these digestive and metabolic processes.
Studies indicate that increased levels of GLP-1 signal to the brain that your appetite is satisfied, thereby aiding in the regulation of food consumption. However, studies suggest that some individuals are resistant to GLP-1. In other cases, their bodies may not produce enough GLP-1 for their brains to tell them they're "full." These individuals are more prone to overeating and gaining weight. If that sounds familiar, treatments like Semaglutide and Tirzepatide can help you better control your appetite.
How Tirzepatide Works
GLP-1 and GIP hormones tell the brain to stop eating. GIP hormones also start processes that help burn the energy gained from eating. This can help improve blood sugar levels and overall fitness. Tirzepatide and similar medicines work like these hormones. When prescribed by a doctor at Interstate Health, Tirzepatide can be a powerful tool to help you lose weight and keep it off for years.
The top benefits of Tirzepatide medical weight loss in Pleasant Prairie, WI include the following:
Long-Term Weight Loss
When combined with a healthy diet and regular exercise, Tirzepatide treatments can help you stop overeating and lose weight in the long term.
Less Chance of Type 2 Diabetes
Obese men and women have a much higher chance of developing Type 2 diabetes. When you lose weight with the help of Tirzepatide, your blood sugar levels become more balanced, and you're less likely to develop the disease.
Enhanced Cardiovascular Health
Like diabetes, obese men and women have much higher rates of cardiovascular issues. By getting healthy with the help of Tirzepatide, your risk of having a stroke, heart attack, and other events is reduced.
Improved Insulin Sensitivity
If you're a truck driver and you have Type 2 diabetes, taking Tirzepatide with guidance from Interstate Health can actually help increase your sensitivity to insulin.
If you're a commercial driver and you're worried about your weight, let this be your sign to do something about it. Contact our Tirzepatide weight loss clinic today to find an Intestate Health conveniently located on your route.
Typical Weight Loss Results When You Take Tirzepatide
If you're interested in Tirzepatide medical weight loss in Pleasant Prairie, WI, you're probably wondering what typical results look like for patients who take the weight loss treatment. It's important for you to know that every patient who takes Tirzepatide will have a unique experience. Your results aren't guaranteed. However, recent studies show very promising results.
In a recent clinical trial, over 2,500 individuals classified as obese or overweight experienced significant weight loss in the first of Tirzepatide's weight loss studies. Participants treated with Tirzepatide experienced an average weight loss of 15% to 20% of their initial body weight over the course of 72 weeks (approximately 16.5 months), which translated to an average weight loss of 34 lbs. to 48 lbs.
In contrast, individuals who received the placebo (an injection with no medication) only experienced an average weight loss of 3%. Furthermore, over a third of participants receiving the highest Tirzepatide dose at 15 mg per week, lost at least 25% of their initial body weight, which is over 58 lbs.
Get Control of Your Appetite with Semaglutide Medical Weight Loss in Pleasant Prairie, WI
Truck drivers who want to lose weight and stay healthy must stick to a consistent exercise routine and healthy diet. But when you're on the road 12 or more hours a day, doing so can be difficult. Between important cargo pick-ups, deliveries, and deadlines, there just doesn't seem to be enough time to find, cook, and eat healthy foods. After all, Wendy's is on the way to your next stop, and you've got to be back on the road quickly to meet other deadlines.
Fortunately, many commercial drivers find Semaglutide to be an incredibly valuable tool to kickstart their weight loss and stay healthy. This injection is FDA-approved for treating diabetes and obesity. Like Tirzepatide, it works by activating GLP-1 receptors in your brain.
Here's What Makes Semaglutide so Effective
Semaglutide is so successful for overweight drivers because it mimics glucagon. It tells your brain that you're full and don't need to eat more. This makes you feel full, reducing the likelihood of overeating, especially at night. Semaglutide also slows down digestion, cutting down on unnecessary snacking throughout the day. Reducing glucose spikes after meals lowers inflammation, which is an important step in improving overall health. Additionally, Semaglutide helps with insulin secretion by the pancreas, regulates glucose levels, and has anti-aging and longevity properties. If you've tried to lose weight with popular diets and unproven pills, medical weight loss with Semaglutide could be the difference-maker you need.
At a glance, Semaglutide helps you lose weight in a few ways, such as:
Semaglutide slows down the amount of food your stomach empties when you're done eating. This delayed emptying makes it feel like you're full, long after you've put away your food.
Semaglutide curbs your cravings and helps you turn down unhealthy, non-nutritious food. On average, patients taking Semaglutide consume around 30% less food than they would without it.
Semaglutide lowers your blood sugar levels without causing them to crash.
Clinical Studies Supporting Semaglutide Medical Weight Loss in Pleasant Prairie, WI
As one of the few healthcare clinics available in rural areas and along trucking routes, we often get questions from members of the community about our medical weight loss plans. One of the most-asked questions we get revolves around whether there are clinical studies relating to Semaglutide. As an FDA-approved treatment, many trials have been conducted to measure the efficacy of weight loss with Semaglutide. The results are eye-opening.
Findings from STEP Trials
A phase 3 randomized clinical trial found that Semaglutide led to an average weight loss of 12.5%. Over half of participants lost 15% or more.
Effective for Long-Term Weight Loss
A trial published in Nature Medicine found that, on average, Semaglutide led to a 10.2% weight reduction after 208 weeks. The study also found that patients who used Semaglutide were able to keep their weight off for up to four years.
Published Data from the NIH
A study published by the National Institutes of Health (NIH) found that patients who took Semaglutide experienced a weight loss percentage of 6.6% after three months and 13.3% after six months.
Better Results Than Placebo
Semaglutide is designed for people who have tried other weight loss methods, have a body mass index (BMI) of 30 or higher, and who want to lose at least 10% of their total body weight. Clinical trials were conducted with 1,900 obese adults who were unable to lose five percent of their body weight after a year of treatment with other medications. Those who took Semaglutide increased average weight loss from 2% to 20% after one year, when compared to the placebo provided.
Patients Lost 31LBS on Average
In a trial with 1,387 patients who were obese but did not have Type 2 diabetes, patients were randomly assigned to different doses of Semaglutide. The dosages ranged from 0.5 mg-1 mg. There was also a placebo that was used. The trial took place for 104 weeks. The group that took the higher dose of Semaglutide lost an average of 31 pounds. Those on the lower dose lost an average of 11 pounds.
What do all these findings mean for you? If you're looking to lose weight in a healthy manner with diet and exercise, it's worth considering Semaglutide medical weight loss in Pleasant Prairie, WI from Interstate Health. Semaglutide isn't a miracle drug, but it can get you started on the right path with promising results that you can use to build momentum. That's why our weight loss practitioners include Semaglutide as a treatment choice for people struggling with obesity - especially those who've tried other treatments but have had little to no success.
How Weight Loss Doctors from Interstate Health Help Truck Drivers Like You
In the competitive world of truck driving, taking care of one's health can often be overlooked due to the demands of the job. Long hours on the road, unpredictable schedules, and limited access to healthy food choices can make it difficult for truck drivers to prioritize their well-being. However, with a personalized medical weight loss plan, truck drivers can begin a journey toward improved health and vitality.
Here's how weight loss doctors can make a significant difference in your life as a truck driver:
Keep on Trucking with Medical Weight Loss from Interstate Health
Research shows that over half of truck drivers are overweight, and up to 70% are considered obese. Carrying that extra weight increases the risk of major health issues like high blood pressure and diabetes. Other studies have found that being obese is linked to a higher risk of being in a crash, as well as facing more severe injuries and a greater chance of death if a crash happens.
If you drive a truck for a living, losing weight isn't just about looking and feeling better - it's also about staying safer on the road. If you're interested in improving your health and losing weight, now is the time to get started. The good news is that weight loss doctors from Interstate Health can help you take the first step toward healthy living. With treatments like Semaglutide and Tirzepatide, your weight loss journey doesn't have to be an uphill battle. Contact an Interstate Health location near you to get started today.
Latest News in Pleasant Prairie, WI
Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars
Patrick Wingrovehttps://www.reuters.com/business/healthcare-pharmaceuticals/lilly-invests-3-billion-expand-wisconsin-plant-obesity-drug-demand-soars-2024-12-05/
Dec 5 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.The new investment in the factory, which it ...
Dec 5 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.
The new investment in the factory, which it acquired from Nexus Pharmaceuticals, will help boost production of Lilly's powerful weight-loss drug Zepbound as well as its diabetes treatments and other medicines, the company said.
“Today's announcement represents our single largest U.S. manufacturing investment outside our home state of Indiana and will add to our ability to expand capacity to make both our existing and future pipeline of medicines,” said Edgardo Hernandez, Lilly's president of global manufacturing.
Zepbound and Lilly's diabetes drug Mounjaro, both known chemically as tirzepatide, were in shortage in the U.S. for much of this year. The U.S. Food and Drug Administration removed tirzepatide from its shortage list earlier this year but is reconsidering that decision following a lawsuit from an industry group representing compounding pharmacies that make and sell versions of the drug not approved by the FDA.
Zepbound was introduced in the U.S. in late 2023. More than 5.2 million prescriptions have since been written for the drug, according to data from IQVIA (IQV.N), opens new tab shared by an analyst.
Lilly said it has committed a total of more than $23 billion to building, expanding and buying manufacturing sites since 2020. The acquisition, expansion, and additional purchases of land and the adjacent warehouse in Wisconsin bring Lilly’s total planned investment in the site to $4 billion, it said.
Lilly, which has become the world's most valuable healthcare company worth over $790 billion, said it plans to start construction on the expansion next year, and previously said it expects production at the facility to begin at the end of 2025.
The company said it expects to add 750 jobs to the Wisconsin plant, which already has more than 100, including operators, technicians, engineers and scientists.
Danish rival Novo Nordisk (NOVOb.CO), opens new tab has also invested billions in manufacturing to ramp up supply of its popular weight-loss drug Wegovy, announcing it would take over three sites from contract manufacturer Catalent (CTLT.N), opens new tab for $11 billion earlier this year.
Reporting by Patrick Wingrove in New York Editing by Bill Berkrot
Gov Evers Eli Lilly And Company Celebrate 3 Billion Expansion Of Manufacturing Facility In Wisconsin
WEDChttps://wedc.org/gov-evers-eli-lilly-and-company-celebrate-3-billion-expansion-of-manufacturing-facility-in-wisconsin/
According to the company, the investment will benefit millions of patients worldwide create 2,000 construction jobs and add 750 highly skilled jobs to Southeastern WisconsinKENOSHA — Gov. Tony Evers today joined Eli Lilly and Company officials to announce a $3 billion expansion of the Kenosha County manufacturing facility that the company acquired earlier t...
According to the company, the investment will benefit millions of patients worldwide create 2,000 construction jobs and add 750 highly skilled jobs to Southeastern Wisconsin
KENOSHA — Gov. Tony Evers today joined Eli Lilly and Company officials to announce a $3 billion expansion of the Kenosha County manufacturing facility that the company acquired earlier this year. According to Lilly, this investment will extend the company’s global parenteral (injectable) product manufacturing network, helping to meet the growing demand for its diabetes, obesity, and future pipeline medicines across therapeutic areas. Lilly expects to add 750 highly skilled jobs to the current 130-plus workforce at this location in Southeastern Wisconsin.
“Southeastern Wisconsin has seen tremendous growth over the past year with major companies announcing significant expansions, and we are thrilled to add Lilly to that growing list with their $3 billion expansion that will add 750 highly-skilled, family-supporting jobs to Kenosha County,” said Gov. Evers. “As a U.S. Regional Tech Hub, Wisconsin is a national leader in personalized medicine and biohealth, and through this partnership with Lilly, we’re going to keep advancing research and innovation and bolstering Wisconsin’s manufacturing industry, all while supporting workers, families, and patients across the state and the world.”
“Today’s announcement represents our single largest U.S. manufacturing investment outside our home state of Indiana and will add to our ability to expand capacity to make both our existing and future pipeline of medicines right here in the Midwest,” said Executive Vice President and President of Lilly Manufacturing Operations Edgardo Hernandez. “We look forward to bringing high-wage, advanced manufacturing, engineering and science jobs to people in Wisconsin, a state that is becoming a critical geography in our global manufacturing operations.”
“Wisconsin’s status as a Regional Tech Hub in biohealth makes it a perfect fit for an innovative, blue-chip company like Eli Lilly,” said Wisconsin Economic Development Corporation (WEDC) Secretary and CEO Missy Hughes, the state’s leading economic development organization. “WEDC worked closely with Eli Lilly to meet its site selection and workforce needs, and we look forward to partnering with them to ensure their success in our state.”
The company plans to start construction on the expansion next year, creating an expected 2,000 construction jobs. This represents another step in Lilly’s historic manufacturing expansion agenda to help more people who depend on its medicines. Since 2020, Lilly has committed more than $23 billion to construct, expand, and acquire manufacturing sites worldwide.
This announcement comes as, in 2019, Gov. Evers joined the owners of Nexus Pharmaceuticals Inc. and local leaders to announce that Nexus selected Pleasant Prairie as the location for its first sterile drug manufacturing facility. WEDC provided $1.5 million in performance-based tax credits to assist Nexus in building the $100 million, 84,000-square-foot facility in Kenosha County to manufacture sterile, injectable drugs—the first such facility built in the nation in more than 30 years. In 2021, Gov. Evers joined Nexus for the ribbon-cutting of the facility, and earlier this year, Lilly announced it was acquiring the manufacturing facility from Nexus. According to Lilly, the acquisition, expansion, and additional purchases of land and the adjacent warehouse in Pleasant Prairie bring Lilly’s total planned investment in Wisconsin to $4 billion. The expanded facility will focus on manufacturing injectable medicines, device assembly, and packaging for medicines across multiple therapeutic areas.
Lilly will use advanced automation, including guided vehicles, robotics, and production equipment, to accelerate medicine production. From data management to operations, digital automation will be embedded throughout the site to accelerate processes and increase accuracy, allowing employees to focus on making safe, high-quality medicines. Lilly also aims to advance innovation in pharmaceutical manufacturing by fostering partnerships with local higher education institutions and supporting various community initiatives in Southeastern Wisconsin.
Wisconsin is a national leader in the biohealth technology sector, and today’s announcement comes as earlier this year, Wisconsin was selected as a U.S. Regional Tech Hub by the U.S. Economic Development Administration, unlocking $49 million to grow the state’s personalized medicine and biohealth sector, including advancing research and innovation, growing the state’s economy and creating jobs, and boosting American competitiveness in a cutting-edge industry. The coveted designation, made possible by years of advocacy from Gov. Evers and U.S. Sen. Tammy Baldwin (D-Wisconsin), will allow Wisconsin’s consortium of 18 public and private partners organized by the Evers Administration through the Wisconsin Economic Development Corporation (WEDC) to boost research and expand lab space, increase coordination and collaboration, improve access to capital to start and grow businesses, and further build out the personalized medicine and biohealth technology sector. Over the first 10 years, the Tech Hub designation is projected to create more than 30,000 jobs in the personalized medicine sector and over 111,000 indirect jobs attributable to the Tech Hub in Wisconsin. Additionally, the Tech Hub is projected to create $9 billion worth of economic development in Wisconsin within the first decade.
Additionally, this year, Southeastern Wisconsin has seen outstanding investments from major global companies. In June, Gov. Evers joined officials from the Kikkoman Corporation for a groundbreaking ceremony for Kikkoman Foods Inc.’s new state-of-the-art manufacturing and production facility in Jefferson. Kikkoman is investing more than $560 million to build this new facility in Jefferson, and together with an additional nearly $250 million expansion effort at the company’s existing facility in Walworth, the projects are expected to create at least 83 new high-paying jobs in Wisconsin over the next 12 years.
Further, in May, Gov. Evers welcomed President Joe Biden to Wisconsin to join Microsoft officials in celebrating the company’s investment of $3.3 billion to expand its national cloud and artificial intelligence (AI) infrastructure capacity through the development of a state-of-the-art datacenter campus in Mount Pleasant and an AI Co-Innovation Lab on the campus of the University of Wisconsin-Milwaukee, the first of its kind in the United States. The project is expected to bring 2,000 union construction jobs to the area by the end of this year, as well as provide long-term employment opportunities over the next several years.
Finally, in April, Gov. Evers announced that Nestlé Purina PetCare Company, which feeds more than 46 million dogs and 68 million cats every year, is expanding its production facility in Jefferson—a $195 million project that will increase production of wet pet food brands in Jefferson by nearly 50 percent and is expected to bring an additional 100 jobs to the community it has called home since 1910. An online version of this release is available here.
Eli Lilly to spend $3 billion, add 750 employees in Kenosha County expansion
Milwaukee Business Journalhttps://www.bizjournals.com/milwaukee/news/2024/12/05/eli-lilly-3b-750-employes-pleasant-prairie-expand.html
Souring demand for Zepbound, Mounjaro has Eli Lilly planning a $3B expansion that will bring hundreds of jobs to Pleasant Prairie, which the company says is part of its 'critical geography.'Drugmaker Eli Lilly and Co. will invest $3 billion and add 750 employees in Kenosha County as the company expands a plant it acquired in April.The Indianapolis-based company (NYSE: LLY) announced Thursday it plans to start the expansion project in 2025.The investment will extend Lilly’s global parenteral (injectable) product man...
Souring demand for Zepbound, Mounjaro has Eli Lilly planning a $3B expansion that will bring hundreds of jobs to Pleasant Prairie, which the company says is part of its 'critical geography.'
Drugmaker Eli Lilly and Co. will invest $3 billion and add 750 employees in Kenosha County as the company expands a plant it acquired in April.
The Indianapolis-based company (NYSE: LLY) announced Thursday it plans to start the expansion project in 2025.
The investment will extend Lilly’s global parenteral (injectable) product manufacturing network, which the company said will help to meet growing demand for its diabetes, obesity and future pipeline medicines across therapeutic areas.
“Today’s announcement represents our single largest U.S. manufacturing investment outside our home state of Indiana and will add to our ability to expand capacity to make both our existing and future pipeline of medicines right here in the Midwest,” Edgardo Hernandez, president of Lilly manufacturing operations, said in a press release. “We look forward to bringing high-wage, advanced manufacturing, engineering and science jobs to people in Wisconsin, a state that is becoming a critical geography in our global manufacturing operations.”
The acquisition, expansion and additional purchases of land and the adjacent warehouse bring Lilly’s total planned investment in Wisconsin to $4 billion, the company said.
The expanded facility in Pleasant Prairie will focus on manufacturing injectable medicines, device assembly and packaging for medicines across multiple therapeutic areas. The company has a 100-plus workforce in Pleasant Prairie.
In April, Lilly reached an agreement to buy a pharmaceutical manufacturing facility from Nexus Pharmaceuticals LLC. Lilly said it would use the 84,000-square-foot site at 10300 128th Ave. in the Prairie Highlands Corporate Park for injectable medicine manufacturing.
That will be the site of the $3 billion expansion project.
DOWNLOAD the free MBJ app for breaking news alerts on your phone
Then in early November, Lilly closed on the $40.8 million purchase of another Kenosha County industrial building on 21.6 acres at 10121 136th Ave. in the village of Bristol. The warehouse, which was built almost a year ago, spans around 325,000 square feet, according to Jim Purinton of Illinois-based Janko Group LLC, which sold the site to Eli Lilly.
The drugmaker also bought two vacant parcels adjacent to the Bristol property, including a 15-acre site to the north and a 16-acre site to the south, Purinton said. Those sites have approvals for additional industrial buildings that could add a combined roughly 525,000 square feet, he said.
The combined 53-acre property Lilly bought in Bristol is just west of the manufacturing facility in Pleasant Prairie.
Lilly said it will use advanced automation, including guided vehicles, robotics and production equipment, to accelerate medicine production in Pleasant Prairie. From data management to operations, digital automation will be embedded to accelerate processes and increase accuracy, allowing employees to focus on making safe, high-quality medicines, the company said.
The new jobs will be in highly skilled roles including operators, technicians, engineers and scientists.
Lilly said it aims to advance innovation in pharmaceutical manufacturing by fostering partnerships with local higher education institutions and supporting community initiatives in Wisconsin.
The company has been investing heavily since 2020 in expanding its capacity — announcing commitments of over $16 billion to develop new manufacturing sites in the U.S. and Europe. Newer locations include Research Triangle Park and Concord, North Carolina; Limerick, Ireland; and Alzey, Germany.
Lilly in May announced investing $5.3 billion at its Lebanon, Indiana, manufacturing site. That Indiana expansion will enhance Lilly's capacity to manufacture active pharmaceutical ingredients for Zepbound (tirzepatide) injection and Mounjaro (tirzepatide), the company said.
Lilly posted revenue of $31.5 billion through the first nine months of 2024, compared with $24.8 billion during the same period in 2023.
The company had about 43,000 employees worldwide as of year-end 2023, with about 20,000 in the United States, according to the company’s latest Form 10-K annual report.
The company owned 11 production, distribution and corporate administrative sites in the United States, including Puerto Rico, as of year-end 2023. At the time, Lilly said its major production sites included Indianapolis; Carolina, Puerto Rico; Durham, North Carolina; and Branchburg, New Jersey.
Largest Milwaukee-area manufacturing firms
Local employees
| Rank | Prior Rank | Business name |
|---|---|---|
| 1 | 2 | GE HealthCare |
| 2 | 3 | Milwaukee Tool |
| 3 | 1 | Quad |
Construction on 705 new Pleasant Prairie homes to start in early 2025
Milwaukee Business Journalhttps://www.bizjournals.com/milwaukee/news/2024/11/21/pleasant-prairie-highland-estates-construction.html
Developer Sanjay Kuttemperoor plans a total of 705 homes in a new Pleasant Prairie subdivision known as Highland Estates.Construction on a new Pleasant Prairie subdivision with 705 homes is expected to begin early next year.The Pleasant Prairie Plan Commission this week approved the final plat and improvement plans for the first phase of the Highland Estates subdivision, paving the way for the developer to move forward. It needs final approval by the Village Board, which could vote Nov. 25.One of the largest subdivisions...
Developer Sanjay Kuttemperoor plans a total of 705 homes in a new Pleasant Prairie subdivision known as Highland Estates.
Construction on a new Pleasant Prairie subdivision with 705 homes is expected to begin early next year.
The Pleasant Prairie Plan Commission this week approved the final plat and improvement plans for the first phase of the Highland Estates subdivision, paving the way for the developer to move forward. It needs final approval by the Village Board, which could vote Nov. 25.
One of the largest subdivisions planned in southeast Wisconsin, the project aims to inject a mix of housing types into the market over the next decade as the area faces a housing shortage. A total of five phases are planned through 2034, according to the village.
"The area needs housing in order to bolster the economic development that's happening," said developer Sanjay Kuttemperoor of ZL River Development LLC and Arbor Estates Group LLC. "What are employers going to do if they move to the area and there’s no housing for their employees?"
The first phase is planned to include 108 single-family homes at four different price points, with the least-expensive homes estimated to start in the mid-$500,000s and the priciest homes expected to start at around $850,000, Kuttemperoor said.
Mass grading for the first phase is expected to start in the first quarter of 2025 and would be followed by sewer, water and stormwater infrastructure improvements, Kuttemperoor said. The site is between 93rd and 104th streets, west of the existing Devonshire and Village Green Heights subdivisions.
The first lots could be ready for homebuilding by the third quarter of 2025, Kuttemperoor said. Arbor Estates Group intends to sell lots to homebuilders and directly to consumers, and is already taking reservations, he said. He declined to share the names of builders.
DOWNLOAD the free MBJ app for breaking news alerts on your phone
Kuttemperoor in May of 2023 proposed the Highland Estates subdivision. It's slated to have a total of 449 single-family homes, 176 duplex units, and 80 condominium units. The duplexes are intended to have owners living on one side and renters on the other, Kuttemperoor said.
Kuttemperoor and his family have a long history of development in southeast Wisconsin. Sanjay's father, Vincent Kuttemperoor of VK Development, was once a prolific Milwaukee-area real estate developer. In the late '90s, for instance, the family developed a 420-acre Pleasant Prairie project known as Prairie Ridge.
But the company was hit hard during the Great Recession. Brookfield-based VK Development, which Sanjay was involved with, surrendered most of its properties to avoid bankruptcy in 2011.
Largest residential property management firms
Units, local
| Rank | Prior Rank | Business name |
|---|---|---|
| 1 | 3 | Hunt Management Inc. |
| 2 | 1 | Ogden & Co. Inc. |
| 3 | 2 | Prospect Management, a division of Sentry Management Inc. |
Disclaimer:
